[go: up one dir, main page]

ZA202007072B - Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof - Google Patents

Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof

Info

Publication number
ZA202007072B
ZA202007072B ZA2020/07072A ZA202007072A ZA202007072B ZA 202007072 B ZA202007072 B ZA 202007072B ZA 2020/07072 A ZA2020/07072 A ZA 2020/07072A ZA 202007072 A ZA202007072 A ZA 202007072A ZA 202007072 B ZA202007072 B ZA 202007072B
Authority
ZA
South Africa
Prior art keywords
preparation
method therefor
application
inhibitor containing
tricyclic derivative
Prior art date
Application number
ZA2020/07072A
Inventor
Peng Gao
Guangjun Sun
Shaobao Wang
Wenhua Xiu
Songliang Tan
Rudi Bao
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of ZA202007072B publication Critical patent/ZA202007072B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

An inhibitor containing a tricyclic derivative, a preparation method therefor and a pharmaceutical composition comprising the inhibitor, as well as a use thereof as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer and diseases or conditions mediated by or dependent on PI3K imbalance.
ZA2020/07072A 2018-05-30 2020-11-12 Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof ZA202007072B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810541998 2018-05-30
CN201810772171 2018-07-13
CN201811142142 2018-09-28
CN201910176302 2019-03-08
PCT/CN2019/088788 WO2019228341A1 (en) 2018-05-30 2019-05-28 Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof

Publications (1)

Publication Number Publication Date
ZA202007072B true ZA202007072B (en) 2025-04-30

Family

ID=68697821

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/07072A ZA202007072B (en) 2018-05-30 2020-11-12 Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof

Country Status (12)

Country Link
US (1) US20210221822A1 (en)
EP (1) EP3805231B1 (en)
JP (2) JP7456945B2 (en)
KR (1) KR102765889B1 (en)
CN (2) CN110785423B (en)
AU (1) AU2019276514B2 (en)
BR (1) BR112020022328A2 (en)
CA (1) CA3101227A1 (en)
MX (1) MX2020012347A (en)
TW (1) TWI891602B (en)
WO (1) WO2019228341A1 (en)
ZA (1) ZA202007072B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250144505A (en) 2018-12-19 2025-10-10 셀진 코포레이션 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2020132016A1 (en) 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2021088845A1 (en) * 2019-11-04 2021-05-14 贝达药业股份有限公司 Imidazolidinone compound and preparation method and application thereof
CN114569619A (en) * 2020-12-01 2022-06-03 上海翰森生物医药科技有限公司 Application of PI3K inhibitor alone or in combination with EGFR inhibitor in preparation of medicines for treating head and neck cancer or gastric cancer
WO2022161347A1 (en) * 2021-01-29 2022-08-04 南京明德新药研发有限公司 Tricyclic compounds and use thereof
CN115181114A (en) * 2021-04-07 2022-10-14 江苏豪森药业集团有限公司 Preparation method of thiazolidone-containing tricyclic compound
CN115181075A (en) * 2021-04-07 2022-10-14 江苏豪森药业集团有限公司 Thiazolidinone derivatives and preparation method thereof
EP4347574A1 (en) * 2021-05-28 2024-04-10 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
WO2023039068A1 (en) * 2021-09-08 2023-03-16 Neubase Therapeutics, Inc. Compositions and methods for synthesis of peptide nucleic acid intermediates
WO2024022435A1 (en) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 Crystal form of 5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine compound and preparation method therefor
WO2024104435A1 (en) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 TRICYCLIC PI3Kα INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF
WO2025237374A1 (en) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
CN121108069A (en) * 2025-11-14 2025-12-12 苏州美诺医药科技有限公司 A method for preparing ethyl-1-oxo-4-azaspirocyclic [5.5]undecane-9-carboxylic acid ethyl ester and its homologues.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (en) 2008-09-10 2014-01-10 Новартис Аг PYROLIDINDICARBONIC ACID DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PROLIFERATIVE DISEASES
PE20121148A1 (en) 2009-08-17 2012-09-07 Intellikine Llc HETEROCYCLIC COMPOUNDS AND USES OF THEM
EP2845592A1 (en) * 2009-09-28 2015-03-11 F. Hoffmann-La Roche AG Benzoxazepin PI3K inhibitor compounds and methods of use
WO2012126901A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
KR20160027217A (en) * 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 Compositions and methods of obtaining and using endoderm and hepatocyte cells
GB201505658D0 (en) * 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
PL3567045T3 (en) * 2015-07-02 2022-04-19 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
EP3317283B1 (en) * 2015-07-02 2019-04-03 H. Hoffnabb-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
WO2018072707A1 (en) * 2016-10-18 2018-04-26 保诺科技（北京）有限公司 Aromatic ether derivative, preparation method therefor, and medical applications thereof

Also Published As

Publication number Publication date
AU2019276514B2 (en) 2023-12-14
BR112020022328A2 (en) 2021-02-02
AU2019276514A1 (en) 2020-11-26
EP3805231A4 (en) 2022-01-12
CA3101227A1 (en) 2019-12-05
KR20210018304A (en) 2021-02-17
CN114835729B (en) 2024-05-31
JP2024083359A (en) 2024-06-21
CN110785423A (en) 2020-02-11
KR102765889B1 (en) 2025-02-11
JP2021525252A (en) 2021-09-24
WO2019228341A1 (en) 2019-12-05
JP7456945B2 (en) 2024-03-27
US20210221822A1 (en) 2021-07-22
MX2020012347A (en) 2021-01-29
TW202016120A (en) 2020-05-01
CN114835729A (en) 2022-08-02
CN110785423B (en) 2022-07-26
EP3805231B1 (en) 2024-10-16
EP3805231C0 (en) 2024-10-16
EP3805231A1 (en) 2021-04-14
TWI891602B (en) 2025-08-01

Similar Documents

Publication Publication Date Title
ZA202007072B (en) Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
MX2018005019A (en) Benzofuran derivative, preparation method thereof and use thereof in medicine.
MX2023010326A (en) Atf6 inhibitors and uses thereof.
TW201613644A (en) Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
WO2018226622A8 (en) Compounds for treating huntington's disease
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914678A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
GEP20207126B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017001656A (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof.
GEAP202014945A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
EP4520395A3 (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
GEP20247585B (en) Furoindazole derivatives
MX2020011826A (en) COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF.
MX376090B (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors
EP4086250A3 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CR20190391A (en) Pyrazole derivatives as bromodomain inhibitors
UA120083C2 (en) ANTIMETASTATIC 2H-SELENOPHENO[3,2-h]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS
MX2019004822A (en) 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof.
SG11201901617PA (en) Azole compound ophthalmic preparation
MX2018005515A (en) 1,4-dicarbonyl-piperidyl derivatives.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents